Domov › Mielofibroza › Texas › Houston
Klinične študije za Mielofibroza v Houston, TX
19 študij za Mielofibroza išče udeležence na lokacijah v Houston in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Vključevanje udeležencevFaza 1/2
- MD Anderson Cancer Center, Houston
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Vključevanje udeležencevFaza 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Vključevanje udeležencevFaza 1
- The University of Texas, MD Anderson Cancer Center, Houston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Vključevanje udeležencevFaza 3
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- LUMI Research, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Vključevanje udeležencevFaza 1/2
- MD Anderson, Houston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Vključevanje udeležencevFaza 1
- MD Anderson Cancer Center, Houston
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Vključevanje udeležencevFaza 2
- MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Vključevanje udeležencevFaza 1
- University of Texas M. D. Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Vključevanje udeležencevFaza 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Vključevanje udeležencevFaza 1/2
- MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Vključevanje udeležencevFaza 1
- MD Anderson Cancer Center, Houston
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Vključevanje udeležencevFaza 2
- GSK Investigational Site, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Vključevanje udeležencevFaza 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Vključevanje udeležencevFaza 2
- MD Anderson, Houston
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Vključevanje udeležencevFaza 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Houston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Vključevanje udeležencevFaza 3
- U.T. MD Anderson Cancer Center, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Vključevanje udeležencevFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Vključevanje udeležencevFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Študije za Mielofibroza v drugih mestih
- New York City, NY18 študij
- Boston, MA12 študij
- Durham, NC12 študij
- Columbus, OH11 študij
- Seattle, WA11 študij
- Salt Lake City, UT10 študij
- Miami, FL10 študij
- Nashville, TN9 študij
- Cleveland, OH9 študij
- Tampa, FL9 študij
- Atlanta, GA9 študij
- Baldwin Park, CA9 študij
Druge študije v Houston
- Nemalicelični pljučni rak145 študij
- Rak dojke126 študij
- Rak (vse vrste)121 študij
- Metastatski rak104 študij
- Kolorektalni rak102 študij
- Rak jajčnikov89 študij
- Akutna mieločna levkemija85 študij
- Rak pljuč78 študij
- Rak prostate76 študij
- Rak endometrija68 študij
- Rak trebušne slinavke61 študij
- Melanom59 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.